Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Parkman Healthcare Partners LLC, a ten percent owner of Spruce Biosciences NASDAQ:SPRB, reported selling 257 shares of common stock on October 6, 2025. The sales, which totaled $4920, were executed in multiple transactions at prices ranging from $17.4557 to $19.3264. The trading activity comes amid significant stock momentum, with SPRB showing a remarkable 1,761% return over the past week. According to InvestingPro analysis, the stock appears overvalued at current levels, with 15+ additional insights available to subscribers.
The firm also purchased 256 shares of Spruce Biosciences common stock at $17.9108, for a total of $4585. Following these transactions, Parkman Healthcare Partners LLC holds 1050 shares of Spruce Biosciences. The company maintains strong liquidity with a current ratio of 2.6, though it faces profitability challenges with negative earnings in the last twelve months.
In other recent news, Spruce Biosciences has announced a significant development with the completion of a securities purchase agreement, securing approximately $50 million through a private placement. The company plans to use these funds to advance its tralesinidase alfa enzyme replacement therapy for Sanfilippo Syndrome Type B, targeting a biologics license application submission in early 2026 and a potential U.S. commercial launch later that year. Additionally, Spruce Biosciences received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the same therapy, a status that could expedite its development and regulatory review. This designation was supported by clinical data showing normalization in cerebral spinal fluid heparan sulfate non-reducing end, which the FDA indicated could serve as a surrogate biomarker for predicting clinical benefits. The company recently resumed trading on the Nasdaq Capital Market under the ticker symbol SPRB. These developments indicate ongoing progress in Spruce Biosciences’ efforts to address serious neurological conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.